COVID-19 vaccine production may start on an industrial scale at Polish biotech firm Mabion in the third quarter of this year, the head of the Polish Development Fund told the Money.pl website on Wednesday.
"As far as I know, the transfer of production technology for these vaccines is currently ongoing and should be finished by June," Paweł Borys told the portal. "If the test series are produced and accepted, then in the third quarter production can start on an industrial scale."
Mabion closed a deal with the company Novavax in March concerning technology transfer and technical production trials of a COVID-19 vaccine on a commercial scale. It was announced at the time that the technology transfer and verification process should be completed in the first half of 2021.
The company also signed an agreement with the Polish Development Fund concerning investment by the fund to the tune of PLN 40 million (EUR 8.71 million). It is earmarked for increasing Mabion's production capacity, specifically for the needs of possible wider cooperation with Novavax.